Skip to main content

Advertisement

Table 1 Basic characteristics of 134 non-small cell lung cancer patients with brain metastases

From: Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study

Characteristics All (N = 134) Gefitinib (N = 62) Erlotinib (N = 49) Afatinib (N = 23) p value
Age > 65 years old 61 (45.5%) 29 (46.8%) (38–93 yr) 26 (53.1%) (41–86 yr) 6 (26.1%) (42–81 yr) .097
Male sex 38 (28.4%) 17 (27.4%) 13 (26.5%) 8 (34.8%) .750
Smoking 16 (11.9%) 8 (12.9%) 4 (8.2%) 4 (17.4%) .504
EGFR mutation status .046
 L858R 56 (41.8%) 26 (41.9%) 26 (53.1%) 4 (17.4%)  
 Del 19 69 (51.5%) 31 (50.0%) 21 (42.9%) 17 (74.0%)  
 Uncommon mutation 5 (3.7%) 3 (4.8%) 2 (4.1%) 0  
 Complex mutations 4 (3.0%) 2 (3.2%) 0 2 (8.7%)  
Initial brain metastases number ≥ 3 88 (65.7%) 33 (53.2%) 33 (67.3%) 15 (65.2%) .527
Other metastastic location
 Lung 54 (40.3%) 24 (38.7%) 21 (42.9%) 9 (39.1%) .900
 Bone 87 (64.9%) 42 (67.7%) 32 (65.3%) 13 (56.5%) .627
 Liver 26 (19.4%) 8 (12.9%) 12 (24.5%) 6 (26.1%) .208
 Pleura 35 (26.1%) 21 (33.9%) 8 (16.3%) 6 (26.1%) .113
 Other location 23 (17.2%) 5 (8.1%) 12 (24.5%) 6 (26.1%) .034
M1c (definition by AJCC 8th edition) 123 (91.8%) 56 (90.3%) 48 (98.0%) 19 (82.6%) .073
Radiotherapy to brain metastases 38 (29.1%) 24 (38.7%) 13 (26.5%) 2 (8.7%) .018
Brain tumor excision 8 (6.0%) 7 (11.3%) 1 (2.0%) 0 .052